Skip to main content
Fig. 7 | BMC Medicine

Fig. 7

From: Combined homologous recombination repair deficiency and immune activation analysis for predicting intensified responses of anthracycline, cyclophosphamide and taxane chemotherapy in triple-negative breast cancer

Fig. 7

Combined status contributes to ACT response and clinical prognosis of TNBC patients. A Hazard ratio of HRD expression signature was calculated using Cox regression model. Log (hazard ratio) > 0 indicates a risk factor (red); log (hazard ratio) < 0 indicates a protective factor (blue). B Performance evaluation that expression signature predicts HRD using lasso logistic regression in diverse types of breast cancer samples, including TNBC samples (green), breast cancer samples (red) and breast cancer except for TNBC (blue). C Distant relapse-free survival (DRFS) by combined status in GSE25065 TNBC cohort. D, E The bar chart shows the proportion of pCR/RD samples with the combined status in Hess et al. TNBC cohort (D) and GSE41998 TNBC cohort (E). pCR, pathological complete response; RD, residual disease. Neg, negative; Pos, positive. F OS by combined status in the METABRIC cohort. The prognostic of HRDPS alone was shown in Additional file 1: Fig. S8C. G The forest plot shows the combined status as an independent prognostic factor for TNBC patients using multivariate Cox regression analysis (METABRIC cohort)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us